CymaBay Therapeutics Debt to Equity Ratio 2013-2018 | CBAY

Current and historical debt to equity ratio values for CymaBay Therapeutics (CBAY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. CymaBay Therapeutics debt/equity for the three months ending December 31, 2018 was 0.00.
CymaBay Therapeutics Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-12-31 $0.00B $0.17B 0.00
2018-09-30 $0.00B $0.19B 0.00
2018-06-30 $0.00B $0.20B 0.00
2018-03-31 $0.00B $0.21B 0.01
2017-12-31 $0.00B $0.09B 0.04
2017-09-30 $0.00B $0.09B 0.04
2017-06-30 $0.01B $0.00B 2.15
2017-03-31 $0.01B $0.01B 0.58
2016-12-31 $0.01B $0.00B 1.55
2016-09-30 $0.01B $0.01B 0.67
2016-06-30 $0.01B $0.02B 0.49
2016-03-31 $0.01B $0.02B 0.37
2015-12-31 $0.01B $0.03B 0.31
2015-09-30 $0.01B $0.03B 0.28
2015-06-30 $0.00B $0.02B 0.14
2015-03-31 $0.00B $0.02B 0.15
2014-12-31 $0.00B $0.01B 0.23
2014-09-30 $0.00B $0.03B 0.13
2014-06-30 $0.00B $0.01B 0.45
2014-03-31 $0.00B $0.01B 0.36
2013-12-31 $0.00B $0.02B 0.24
2013-09-30 $0.01B $0.02B 0.48
2013-06-30 $0.00B $0.00B 0.00
2013-03-31 $0.00B $0.00B 0.00
2012-12-31 $0.00B $0.00B 0.00
2012-09-30 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.764B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.308B 9.06
Teva Pharmaceutical Industries (TEVA) Israel $16.789B 5.79
Mylan (MYL) United Kingdom $14.493B 6.13
Bausch Health Cos (BHC) Canada $8.388B 5.97
Dr Reddy's Laboratories (RDY) India $6.454B 25.74
Supernus Pharmaceuticals (SUPN) United States $1.988B 18.45
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.826B 2.97
Homology Medicines (FIXX) United States $0.994B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.933B 87.96
Voyager Therapeutics (VYGR) United States $0.641B 0.00
Assembly Biosciences (ASMB) United States $0.517B 0.00
Akorn (AKRX) United States $0.424B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.374B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.214B 0.00
Sol-Gel Technologies (SLGL) Israel $0.129B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.105B 0.00
Acasti Pharma (ACST) Canada $0.084B 0.00
Teligent (TLGT) United States $0.075B 0.00
Agile Therapeutics (AGRX) United States $0.070B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.023B 0.00
Aevi Genomic Medicine (GNMX) United States $0.014B 0.00